{"id":37096,"date":"2026-04-10T11:00:00","date_gmt":"2026-04-10T15:00:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37096"},"modified":"2026-03-08T14:27:46","modified_gmt":"2026-03-08T18:27:46","slug":"the-manufacturing-moat-why-process-patents-are-the-most-undervalued-defense-against-generic-entry","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-manufacturing-moat-why-process-patents-are-the-most-undervalued-defense-against-generic-entry\/","title":{"rendered":"The Manufacturing Moat: Why Process Patents Are the Most Undervalued Defense Against Generic Entry"},"content":{"rendered":"\n

The Hierarchy Problem in Pharmaceutical IP<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every pharmaceutical patent portfolio has a hierarchy, whether the company managing it acknowledges one or not. Compound patents sit at the top. They protect the active ingredient itself \u2014 the molecule \u2014 and when they are valid and broad, they protect everything downstream: every formulation, every dosage form, every manufacturing route that produces the compound. They are the crown jewel of pharmaceutical IP, and they receive attention proportional to that status.<\/p>\n\n\n\n

Then the compound patent expires, and the company discovers what it actually had beneath that patent.<\/p>\n\n\n\n

Process patents \u2014 those covering the chemical synthesis routes, purification methods, bioreactor conditions, and manufacturing steps used to produce a pharmaceutical compound \u2014 occupy a strange position in the valuation literature. Patent attorneys know how to write them. Pharmaceutical scientists know how critical the underlying technology is. But IP analysts conducting portfolio valuations, investment bankers modeling acquisition targets, and strategic planners drawing up competitive timelines routinely discount them to near-zero the moment a compound patent expires, treating them as residual IP with no real commercial function.<\/p>\n\n\n\n

That treatment is wrong, and the cost of being wrong is measured in hundreds of millions of dollars of revenue that companies fail to protect because they never identified the protection they still had.<\/p>\n\n\n\n

This article examines why process patents are undervalued, what they actually protect, how enforcement works in practice, and how a rigorous analytical framework produces dramatically different \u2014 and more accurate \u2014 portfolio valuations than the standard approach of assuming that the expiration of a compound patent is the end of the IP story.<\/p>\n\n\n\n

\n\n\n\n

What Process Patents Actually Cover<\/h2>\n\n\n\n

The term “process patent” encompasses a range of distinct claim types, and the first step toward valuing them correctly is being precise about which category is under discussion. Their commercial implications differ substantially.<\/p>\n\n\n\n

Chemical Synthesis Route Patents<\/h3>\n\n\n\n

A synthesis route patent claims the sequence of chemical steps \u2014 reactions, conditions, reagents, solvents, temperatures, catalytic systems \u2014 used to build a pharmaceutical compound from simpler starting materials. For small-molecule drugs, these routes typically involve multiple reaction steps, each of which transforms an intermediate compound into the next precursor, until the final active pharmaceutical ingredient (API) emerges.<\/p>\n\n\n\n

The economic value of a synthesis route patent rests on a simple question: can a generic manufacturer produce the API without using the patented steps? The answer depends on whether commercially feasible alternative routes exist. For some compounds, synthetic organic chemistry allows multiple distinct pathways to the same final molecule, any one of which could satisfy a generic manufacturer’s cost and purity requirements. For others \u2014 particularly complex chiral molecules, polycyclic structures, or compounds requiring unusual bond formations \u2014 the patented route may be the only one that works at commercial scale.<\/p>\n\n\n\n

Where no feasible alternative route exists, the synthesis route patent functions as a compound patent in practical terms. It does not matter that the compound itself is no longer protected. If producing the compound requires the patented process, generic manufacturers cannot enter the market without either licensing the patent or developing a genuinely novel alternative route, which may take years and cost tens of millions of dollars.<\/p>\n\n\n\n

Purification and Isolation Patents<\/h3>\n\n\n\n

Once a synthesis reaction completes, the crude reaction mixture contains the target compound alongside unreacted starting materials, byproducts, solvent residues, and potentially toxic process-related impurities. Getting from that crude mixture to an API that meets pharmacopoeial purity standards requires purification \u2014 typically through crystallization, chromatography, extraction, or combinations of these techniques.<\/p>\n\n\n\n

Purification patents claim the specific conditions under which this separation occurs. They may specify the solvent system, the temperature gradient, the column chromatography stationary phase, the seeding procedure for crystallization, or the counter-ion used in salt formation. For APIs with unusually complex impurity profiles \u2014 those with genotoxic process impurities, for instance, where trace contamination can trigger regulatory concern \u2014 the purification process that eliminates these impurities to acceptable levels can be the technically most demanding step in the manufacturing sequence.<\/p>\n\n\n\n

ICH Q3A guidelines for new drug substances define strict limits for identified and unidentified impurities, and the 2018 nitrosamine impurity crisis demonstrated in vivid commercial terms what happens when an API purification process fails to eliminate a class of process-related genotoxic impurities [1]. Valsartan, losartan, ranitidine, and metformin products were recalled across multiple jurisdictions. Manufacturers who had developed and patented superior purification processes that eliminated nitrosamine formation pathways held a genuine competitive advantage during that period \u2014 one that regulators’ heightened scrutiny of impurity profiles has made permanent.<\/p>\n\n\n\n

Intermediate Compound Patents<\/h3>\n\n\n\n

Intermediate compounds are the chemical entities produced partway through a synthesis route, before the final API is complete. Claiming an intermediate compound itself \u2014 rather than the process \u2014 can produce patent protection with different legal characteristics and potentially longer commercial reach than a direct process claim.<\/p>\n\n\n\n

An intermediate patent does not require proving that a competitor used the patented process. It requires proving that the competitor’s synthesis pathway went through the patented intermediate structure. For complex synthesis routes where all commercially feasible pathways converge on a common intermediate before diverging to the final product, an intermediate patent can function as an effective chokepoint \u2014 blocking generic entry regardless of which specific reaction conditions the generic manufacturer used upstream of the intermediate.<\/p>\n\n\n\n

This distinction matters for enforcement. Under 35 U.S.C. \u00a7 271(g), proving process patent infringement requires showing that an imported product was “made by” the patented process. Proving intermediate compound infringement involves identifying the intermediate in the competitor’s product or process, which may require different investigative and analytical strategies.<\/p>\n\n\n\n

Biologic Manufacturing Process Patents<\/h3>\n\n\n\n

For biological products \u2014 monoclonal antibodies, recombinant proteins, peptides, and gene therapy vectors \u2014 the process is the product in a more fundamental sense than for small molecules. The International Conference on Harmonisation’s guideline Q5E captures this reality: when a biological manufacturing process changes, the resulting product may change too, in ways that are not always predictable or detectable through standard analytical methods [2].<\/p>\n\n\n\n

Biologic process patents cover the upstream manufacturing processes (cell line development, growth media composition, bioreactor conditions, fed-batch strategies, temperature shift protocols) and the downstream processing steps (centrifugation, filtration, chromatography purification, viral inactivation and clearance, fill-finish operations). Both categories can provide enforceable patent protection, but they operate differently in the competitive landscape.<\/p>\n\n\n\n

Upstream process patents covering proprietary cell lines or growth media formulations can prevent biosimilar manufacturers from replicating the exact conditions used to produce a reference biologic. Since the FDA’s biosimilar approval pathway under the BPCIA requires demonstrating biosimilarity \u2014 not identity \u2014 to the reference product, biosimilar manufacturers are actually expected to use different manufacturing processes. The legal consequence is that upstream process patents on biologic manufacturing may be less directly enforceable than their small-molecule equivalents, because the biosimilar manufacturer can truthfully argue it never used the patented process.<\/p>\n\n\n\n

Downstream processing patents \u2014 particularly those covering novel chromatography sequences or viral clearance methods \u2014 present a different enforcement picture. These steps are often less variable across manufacturers, because regulatory requirements for biosafety set floors on viral clearance performance that constrain the design space. A well-written downstream processing patent can create genuine exclusivity by covering the limited set of approaches that simultaneously satisfy regulatory requirements and operate at commercial scale.<\/p>\n\n\n\n

\n\n\n\n

The Legal Framework: How Process Patents Create Enforceable Rights<\/h2>\n\n\n\n

The commercial value of a process patent depends entirely on whether it can be enforced. For pharmaceutical process patents, the enforcement framework has specific statutory hooks that generic manufacturers and their counsel rarely advertise to the brand companies holding the patents.<\/p>\n\n\n\n

35 U.S.C. \u00a7 271(g): The Importation Statute<\/h3>\n\n\n\n

Section 271(g) of the Patent Act provides that whoever imports a product made by a process patented in the United States infringes that patent [3]. This provision was enacted as part of the Process Patent Amendments Act of 1988 specifically to address the situation \u2014 commercially prevalent in pharmaceuticals \u2014 where a process is practiced abroad to produce a product that is then imported for sale in the United States.<\/p>\n\n\n\n

The commercial geography of pharmaceutical manufacturing makes this statute particularly relevant. The majority of API manufacturing for both branded and generic drugs sold in the United States occurs in India and China. Generic manufacturers based in India and China who use a process patented in the United States to produce an API, then import that API or finished dosage form into the United States, are directly within the scope of \u00a7 271(g).<\/p>\n\n\n\n

The statute contains two limitations that affect its scope. A product is not infringing if it has been “materially changed by subsequent processes” after being made by the patented process, or if it becomes a “trivial and nonessential component” of another product [4]. Generic manufacturers have invoked both limitations. Courts have generally interpreted “materially changed” narrowly \u2014 a subsequent chemical reaction that converts the API to a different chemical form, such as a different salt, may qualify, but standard formulation steps (blending, tableting, coating) do not [5].<\/p>\n\n\n\n

The practical consequence of \u00a7 271(g) is that a brand pharmaceutical manufacturer holding a U.S. process patent on its API synthesis route has a colorable infringement claim against any generic manufacturer whose Indian or Chinese API supplier used that process, regardless of where the API was produced. The claim is not hypothetical \u2014 courts have awarded both damages and injunctions under \u00a7 271(g) in pharmaceutical cases.<\/p>\n\n\n\n

The International Trade Commission: A Faster Path to Exclusion<\/h3>\n\n\n\n

The U.S. International Trade Commission (ITC) provides an alternative enforcement vehicle for process patents that can be faster and more commercially disruptive to generic entrants than district court litigation. Section 337 of the Tariff Act prohibits the importation of articles that infringe a valid U.S. patent, including articles made by patented processes [6].<\/p>\n\n\n\n

ITC Section 337 investigations typically complete within 12-16 months from institution to a final determination \u2014 substantially faster than the three-to-five-year timeline of district court patent litigation [7]. The remedy available at the ITC is an exclusion order, which directs U.S. Customs and Border Protection to block importation of infringing articles at the border. A general exclusion order applies against all importers regardless of whether they were named as respondents; a limited exclusion order applies against specific named respondents.<\/p>\n\n\n\n

For a brand pharmaceutical manufacturer whose patent litigation strategy is to delay generic entry, the ITC offers a specific tactical advantage: seeking an ITC exclusion order while simultaneously pursuing district court litigation creates dual-track pressure on a generic manufacturer. Even if the ITC proceeding does not result in a permanent exclusion order, the investigation period itself \u2014 during which the risk of an import ban is real and pending \u2014 may deter some generic manufacturers from launching at risk.<\/p>\n\n\n\n

The ITC has jurisdiction specifically over the importation of infringing goods, which means the importation hook is essential. For process patents covering API manufacturing that occurs abroad, this hook is readily available. For manufacturing processes practiced entirely within the United States, the ITC is not an available enforcement forum.<\/p>\n\n\n\n

The Burden of Proof Shift in Process Patent Litigation<\/h3>\n\n\n\n

One of the most practically significant \u2014 and least-discussed \u2014 features of process patent law is the evidentiary presumption available under 35 U.S.C. \u00a7 295. When a brand manufacturer has made a reasonable effort to determine the process used to produce a product, and the court finds that the branded product is likely made by the patented process and that substantial likelihood of infringement exists, the burden shifts to the accused infringer to prove that its product was not made by the patented process [8].<\/p>\n\n\n\n

This burden shift is commercially important because the manufacturing processes used by generic API suppliers are typically closely guarded trade secrets. Generic manufacturers do not voluntarily disclose their synthesis routes, and even in litigation, full discovery of manufacturing details from foreign API suppliers involves procedural and jurisdictional complications. The burden shift under \u00a7 295 means that if the brand company can establish the likelihood of infringement \u2014 often through circumstantial evidence including the similar impurity profile of the generic API or disclosed intermediates in the generic’s regulatory submission \u2014 the generic manufacturer must affirmatively prove it used a different process.<\/p>\n\n\n\n

This shifts the litigation dynamics fundamentally. Without \u00a7 295, the brand company must prove infringement \u2014 a difficult task when the allegedly infringing process occurs behind the walls of an Indian or Chinese API facility. With \u00a7 295, the generic manufacturer must prove non-infringement, which requires either disclosing its manufacturing process under protective order or facing an adverse inference.<\/p>\n\n\n\n

\n\n\n\n

Why Generic Manufacturers Cannot Simply Develop Alternative Routes<\/h2>\n\n\n\n

The commercial value of a process patent depends substantially on whether generic manufacturers can develop non-infringing routes on commercially viable timelines and at commercially viable costs. For many pharmaceutical compounds, the answer is “not easily” \u2014 and understanding why requires following the regulatory and technical constraints that lock generic manufacturers into specific manufacturing approaches.<\/p>\n\n\n\n

The Chemistry, Manufacturing, and Controls Lock-In<\/h3>\n\n\n\n

When a generic manufacturer files an Abbreviated New Drug Application (ANDA) with the FDA, the application must specify the manufacturing process for the API and finished dosage form. This specification, contained in the Chemistry, Manufacturing, and Controls (CMC) section of the ANDA, is not merely administrative. It defines what the manufacturer is approved to make. If the manufacturer later wants to change its synthesis route, it must file a prior approval supplement (PAS) with the FDA, obtain approval for the change, and potentially conduct bioequivalence studies if the change could affect the product’s performance [9].<\/p>\n\n\n\n

The CMC approval process for a route change typically takes 12-24 months from submission to approval. During that period, the manufacturer is locked into the originally-approved process. If that process infringes a valid patent, the manufacturer is infringing continuously while waiting for approval to switch to a non-infringing route.<\/p>\n\n\n\n

This regulatory lock-in dramatically extends the window during which a process patent can generate actionable infringement, and therefore during which it can be used as a negotiating tool in licensing discussions. A generic manufacturer that has already invested in building an API manufacturing facility validated for a specific synthesis route, hired and trained operators, and obtained regulatory approval is not going to abandon that investment quickly in response to a process patent assertion. The realistic alternative is to take a license.<\/p>\n\n\n\n

The Validation Cost Barrier<\/h3>\n\n\n\n

Pharmaceutical manufacturing facilities are validated to produce specific products using specific processes. Process validation under FDA’s guidance for industry requires demonstrating that a manufacturing process consistently produces a product meeting its predetermined specifications [10]. Validation for a new synthesis route is not a paper exercise \u2014 it involves pilot-scale and commercial-scale manufacturing runs, analytical method development and validation for the new process, impurity profiling, stability studies for API produced by the new route, and regulatory submission.<\/p>\n\n\n\n

Estimates of the cost of fully validating a new API synthesis route at commercial scale vary considerably depending on the compound’s complexity, but figures in the range of $10 million to $30 million are common for a commercially significant small-molecule API requiring multiple reaction steps and specific purification conditions. For highly complex molecules \u2014 those with multiple stereocenters, unusual functional groups, or demanding purity requirements \u2014 validation costs can substantially exceed this range.<\/p>\n\n\n\n

This validation cost creates an asymmetry. The cost of filing and prosecuting a process patent portfolio covering the commercial synthesis route and its key intermediates typically runs in the low hundreds of thousands of dollars per patent family. The cost of developing and validating a genuinely alternative route to the same API can be one or two orders of magnitude larger. A brand manufacturer that has invested $10 billion in developing a drug can usually justify spending $5 million on process patent prosecution. The economic leverage this creates against generic entry is substantial.<\/p>\n\n\n\n

The API Supplier Geography Problem<\/h3>\n\n\n\n

Most generic manufacturers do not produce the APIs in their products. They purchase APIs from third-party suppliers, predominantly based in India and China, who specialize in API synthesis and may serve multiple generic manufacturers simultaneously. This supply chain structure creates a specific problem for generic manufacturers confronting a process patent assertion.<\/p>\n\n\n\n

A generic manufacturer in the United States that receives a process patent assertion typically cannot quickly evaluate whether its API supplier used the patented process, because the supplier treats its manufacturing process as a proprietary trade secret. The generic manufacturer may not have disclosed its supplier’s process to anyone, including its own legal team. Investigating the question requires either obtaining voluntary disclosure from the supplier \u2014 which the supplier may resist because it would expose trade secrets \u2014 or waiting for court-ordered discovery.<\/p>\n\n\n\n

During this investigative period, the generic manufacturer faces legal uncertainty about whether its product infringes. If it continues selling, it risks enhanced damages for willful infringement if infringement is subsequently established. If it stops selling, it loses market share to competitors. This uncertainty itself has commercial value for the brand company \u2014 it creates a negotiating window during which the generic manufacturer may prefer to take a license on commercially reasonable terms rather than endure the uncertainty and litigation cost.<\/p>\n\n\n\n

DrugPatentWatch’s integration of Orange Book patent listings with ANDA filing data allows analysts to map which generic manufacturers have filed ANDAs for products covered by process patents, and to identify which of those generic manufacturers have also filed Paragraph IV certifications specifically against the process patents. Where Paragraph IV certifications are absent for process-patent-listed products \u2014 meaning the generic manufacturer certified only Paragraph III (that the patent will expire before it seeks approval) rather than challenging validity or non-infringement \u2014 it often signals that the generic manufacturer either believes the process patent is valid and enforceable, or could not develop a credible invalidity argument.<\/p>\n\n\n\n

The Third-Party API Supplier Exposure<\/h3>\n\n\n\n

The process patent infringement risk does not fall solely on the generic finished dosage form manufacturer. The API supplier who actually used the patented process is also a direct infringer under \u00a7 271(a) or (g), depending on whether manufacturing occurred in the United States or abroad. Brand manufacturers have pursued both the generic drug company and its API suppliers in process patent litigation, sometimes obtaining settlements from API suppliers that effectively cut off supply to multiple generic manufacturers simultaneously.<\/p>\n\n\n\n

This multi-defendant strategy can be more efficient than pursuing each generic manufacturer individually, particularly when a single API supplier is producing the allegedly infringing API for multiple generic manufacturers. One successful injunction against the API supplier eliminates the supply source for all its customers at once.<\/p>\n\n\n\n

\n\n\n\n

Case Study 1: The Taxol Manufacturing Patent Wars<\/h2>\n\n\n\n

Paclitaxel \u2014 marketed by Bristol-Myers Squibb as Taxol \u2014 provides one of the clearest historical examples of process patent strategy functioning as a genuine commercial moat after compound patent expiration.<\/p>\n\n\n\n

Bristol-Myers Squibb’s Semi-Synthetic Route<\/h3>\n\n\n\n

The original paclitaxel was extracted from the bark of the Pacific yew tree (Taxus brevifolia), a slow-growing species that was neither sustainable as a commercial supply source nor scalable to meet growing oncology demand. BMS invested substantially in developing a semi-synthetic manufacturing route starting from 10-deacetylbaccatin III (10-DAB), a compound more readily available from the needles and leaves of European yew species and from cultivated Taxus plantations [11].<\/p>\n\n\n\n

The semi-synthetic route represented genuine technical innovation \u2014 converting 10-DAB to paclitaxel required solving non-trivial synthetic organic chemistry problems around selective protection and functionalization of the complex taxane scaffold. BMS filed patents covering not only the semi-synthetic route itself but also key intermediates produced along the route and specific reaction conditions that improved yield and stereoselectivity.<\/p>\n\n\n\n

When the composition-of-matter patents covering paclitaxel expired, the manufacturing patent portfolio did not. Generic manufacturers seeking to produce paclitaxel faced a choice: develop an alternative semi-synthetic route that avoided BMS’s patents, or obtain paclitaxel from an entirely different source. The extraction route was commercially impractical at scale and environmentally constrained. Alternative semi-synthetic routes required solving the same fundamental chemistry problems, which had themselves been the subject of extensive research and now sat under BMS’s patent claims.<\/p>\n\n\n\n

The Commercial Outcome<\/h3>\n\n\n\n

The process patent portfolio did not give BMS permanent monopoly \u2014 the compound was off patent, and the therapeutic imperative for affordable cancer drugs created regulatory and competitive pressure. But it extended BMS’s period of effective manufacturing exclusivity by several years beyond the compound patent expiration, provided leverage in licensing negotiations with generic API suppliers entering the market, and generated royalty revenue from generic manufacturers who found licensing more economical than full route development.<\/p>\n\n\n\n

From a portfolio valuation perspective, the lesson is specific: an analyst who wrote off the Taxol IP portfolio at compound patent expiration would have missed both the direct exclusivity value and the licensing revenue stream that the process patents generated. The semi-synthetic process patents had real commercial value that citation-count analysis \u2014 tracking forward citations to the basic paclitaxel composition patents \u2014 would have attributed to the wrong asset class entirely.<\/p>\n\n\n\n

\n\n\n\n

Case Study 2: Atorvastatin and the Manufacturing Bridge Strategy<\/h2>\n\n\n\n

Atorvastatin, Pfizer’s Lipitor, generated peak annual revenues of approximately $13 billion, making it the best-selling pharmaceutical in history [12]. Its compound patents expired in late 2011, and generic entry followed almost immediately \u2014 Watson Pharmaceuticals launched a generic in November 2011, and within a year, generic atorvastatin had captured over 80 percent of the market by volume.<\/p>\n\n\n\n

What is less frequently analyzed is the manufacturing patent portfolio that existed alongside the compound patents and the strategic choices Pfizer made in how aggressively to deploy it.<\/p>\n\n\n\n

The Atorvastatin Process Portfolio<\/h3>\n\n\n\n

Atorvastatin’s synthesis is not chemically trivial. The molecule contains five stereocenters, and producing it with the required enantioselectivity requires either asymmetric synthesis or chiral resolution steps that were themselves subject to patent protection. Warner-Lambert (acquired by Pfizer) and its research collaborators had filed patents covering the specific asymmetric reduction conditions used to establish the correct stereochemistry at the critical positions, the chiral resolution procedures used to separate enantiomers in earlier-generation synthesis routes, and the key intermediates used in the most commercially efficient routes [13].<\/p>\n\n\n\n

Generic manufacturers developing atorvastatin products in the years before Lipitor’s patent cliff were aware of this process patent landscape. Some chose to develop alternative stereoselective synthesis routes. Others licensed the process technology from the compound patent holder or from API suppliers that had obtained licenses. The process patent portfolio did not prevent generic entry \u2014 the economic and regulatory pressure to allow generic atorvastatin access was simply too great for the process patents alone to hold the line after the compound patent fell \u2014 but it shaped how generic manufacturers entered the market, on what terms, and with what supply chains.<\/p>\n\n\n\n

What Portfolio Analysis Should Have Captured<\/h3>\n\n\n\n

The commercially relevant question in 2009 or 2010, two years before Lipitor’s compound patent expiration, was not merely “when does the compound patent expire?” It was: “After the compound patent expires, what process patent coverage remains, how strong is it, and how much will it cost generic manufacturers to either design around it or license it?”<\/p>\n\n\n\n

A rigorous process patent analysis in 2009 would have produced a probability-weighted estimate of the royalty rate and the licensing universe \u2014 how many generic manufacturers would pay to license the process technology versus invest in alternative route development, and what the resulting royalty revenue stream to Pfizer would look like. That revenue stream, correctly valued, would have contributed meaningfully to the post-2011 IP portfolio valuation.<\/p>\n\n\n\n

The complication, and the reason this analysis is frequently skipped, is that process patent portfolios are harder to value than compound patents. The key uncertainty \u2014 whether a competing route is commercially feasible \u2014 requires chemistry expertise that IP analysts rarely have. This creates a systematic tendency to skip the analysis rather than execute it imperfectly. The result is that process patent portfolios are not discounted for uncertainty; they are ignored entirely.<\/p>\n\n\n\n

\n\n\n\n

Case Study 3: Erythropoietin and the Biologic Manufacturing Moat<\/h2>\n\n\n\n

The history of erythropoietin (EPO) \u2014 the recombinant protein drug used to treat anemia in dialysis and cancer patients \u2014 offers an extended case study in how manufacturing process patents interact with biologic exclusivity.<\/p>\n\n\n\n

The Amgen Process Patent Foundation<\/h3>\n\n\n\n

Amgen developed recombinant human EPO in the 1980s, filing foundational patents on both the DNA sequence coding for EPO and the mammalian cell culture processes used to produce it. The cell expression system patents \u2014 covering the use of Chinese hamster ovary (CHO) cells transfected with specific expression vectors under defined culture conditions \u2014 were separate from and independent of the composition-of-matter patents on the EPO protein itself [14].<\/p>\n\n\n\n

When European biosimilar manufacturers began developing EPO biosimilars in the early 2000s, they could not simply use Amgen’s CHO cell system and culture conditions without risk of infringing the process patents. They had to develop alternative expression systems \u2014 some using different mammalian cell lines, some using modified culture conditions designed to avoid specific claim language \u2014 and demonstrate that the resulting protein had sufficient similarity to the reference product to obtain regulatory approval.<\/p>\n\n\n\n

This development burden imposed by the process patent portfolio did not prevent biosimilar entry indefinitely \u2014 the first EPO biosimilars were approved in Europe in 2007 under the newly established EMA biosimilar pathway \u2014 but it delayed it, increased the cost of biosimilar development, and shaped which manufacturers were able to enter the market. Only large, technically sophisticated manufacturers with significant cell biology capabilities could afford the investment in alternative expression system development required to design around Amgen’s manufacturing patents.<\/p>\n\n\n\n

What the EPO Case Reveals About Biologic Process Patents<\/h3>\n\n\n\n

The EPO litigation history, which extended through multiple jurisdictions and years, produced several findings that are commercially instructive for biologic portfolio valuation.<\/p>\n\n\n\n

First, the granularity of the process claims mattered enormously for enforceability. Broad claims covering “mammalian cell culture” were more vulnerable to prior art challenges than specific claims covering particular media formulations or temperature-shift protocols that Amgen had developed. The narrow but specific claims were the ones that created genuine design-around burdens for biosimilar manufacturers.<\/p>\n\n\n\n

Second, the interaction between U.S. and European patent protection was asymmetric. Amgen’s process patents had different scopes in the United States and Europe due to differences in prosecution history, claim construction standards, and applicable prior art. Biosimilar manufacturers who successfully navigated the European patent landscape still faced separate analysis and potential infringement risk in the United States.<\/p>\n\n\n\n

Third, the regulatory requirements for biosimilar manufacturing quality inadvertently reinforced some of Amgen’s process patent claims. The need to produce a protein with specific glycosylation patterns \u2014 which are cell type and culture condition dependent \u2014 limited the number of expression systems capable of producing a clinically equivalent product. This reduced the population of viable alternative manufacturing approaches that biosimilar developers could use to design around the process patents.<\/p>\n\n\n\n

\n\n\n\n

Valuing Process Patents: A Rigorous Framework<\/h2>\n\n\n\n

Building a defensible value estimate for a pharmaceutical process patent requires working through four analytical steps that are distinct from \u2014 and more technically demanding than \u2014 the claims architecture and term analysis appropriate for compound patents.<\/p>\n\n\n\n

Step 1: Route-Dependency Analysis<\/h3>\n\n\n\n

The foundational question is whether the patented process represents the only commercially viable route to the final API, or whether multiple alternative routes exist with comparable cost and quality profiles. This analysis requires input from medicinal chemistry and process chemistry expertise, and it cannot be delegated entirely to patent attorneys.<\/p>\n\n\n\n

The route-dependency analysis should produce a categorical finding:<\/p>\n\n\n\n

High route dependency: No commercially viable alternative route exists at the time of analysis, and the technical barriers to developing one are significant (estimated development time over three years, estimated cost over $20 million, or both). The process patent’s commercial value approaches that of a compound patent, because generic entry requires licensing or prohibitive alternative development.<\/p>\n\n\n\n

Moderate route dependency: Alternative routes exist but require substantial development investment, ranging from 18 months to three years and $5 million to $20 million. The process patent’s value reflects the licensing premium it can command from generic manufacturers who prefer licensing to development, discounted for the probability that well-resourced generic manufacturers will invest in alternative route development.<\/p>\n\n\n\n

Low route dependency: Multiple commercially feasible alternative routes are known from the literature or obvious to a skilled process chemist, requiring less than 18 months and $5 million to implement. The process patent has limited exclusionary value but may still carry nuisance value in licensing negotiations.<\/p>\n\n\n\n

Executing this analysis requires accessing published synthetic chemistry literature, searching Patent Cooperation Treaty applications and foreign patent filings for disclosed alternative routes (which competitors often file despite not yet commercializing them), and consulting process chemists with experience in the relevant compound class. The literature search component can be significantly accelerated using patent database tools, with DrugPatentWatch providing the pharmaceutical-specific regulatory context that links synthesis route patents to specific marketed products and their ANDA filer landscape.<\/p>\n\n\n\n

Step 2: Regulatory Switching Cost Quantification<\/h3>\n\n\n\n

Even when an alternative synthesis route exists, the regulatory validation requirement creates a switching cost that is economically equivalent to a toll. The process patent holder can demand a licensing fee up to the value of the regulatory switching cost \u2014 because a rational generic manufacturer will license rather than pay more to develop and validate an alternative route.<\/p>\n\n\n\n

Quantifying the regulatory switching cost requires estimating:<\/p>\n\n\n\n

API route development costs: The medicinal chemistry and process chemistry work required to develop and optimize a non-infringing route, including laboratory-scale feasibility work, kilogram-scale optimization, and pilot-scale validation. Industry benchmarks from generic API manufacturers place this cost at $3 million to $8 million for moderately complex small-molecule APIs.<\/p>\n\n\n\n

FDA submission and approval costs: Preparing and submitting a Prior Approval Supplement or New Drug Application amendment for a route change, managing the review period, and responding to FDA queries. This phase typically costs $500,000 to $2 million and takes 12-24 months.<\/p>\n\n\n\n

Opportunity cost of the delay period: For a generic manufacturer already approved and selling a product using the infringing route, the period required to obtain approval for the alternative route is a period of legal uncertainty. Valuing this opportunity cost requires estimating the generic manufacturer’s monthly contribution from the product and the probability that it would choose to continue selling during the dispute period.<\/p>\n\n\n\n

The sum of these three components represents the maximum rational licensing fee \u2014 the amount above which a generic manufacturer would prefer to develop an alternative route rather than license the patented process. This ceiling provides the foundation for a discounted cash flow model of process patent licensing value.<\/p>\n\n\n\n

Step 3: Enforcement Probability Adjustment<\/h3>\n\n\n\n

A process patent’s theoretical value is its licensing ceiling multiplied by the number of potential licensees (generic manufacturers producing the API using the patented process). Its expected value is reduced by the probability that the patent would survive validity challenges, the probability that infringement can be proved against each potential licensee, and the probability that the patent holder will have the resources and commercial interest to enforce it.<\/p>\n\n\n\n

Validity probability should be assessed using the same methodology applied to compound patents: prior art landscape analysis, IPR petition history, and claim scope assessment. Process patents face a specific prior art vulnerability that compound patents do not: synthetic chemistry is a highly documented science, and academic publications describing synthesis routes often predate the patent filing by years. A thorough prior art search for a process patent requires searching chemical databases (SciFinder, Reaxys) as well as patent databases, because the relevant prior art may be a journal article rather than a patent.<\/p>\n\n\n\n

Infringement probability reflects the difficulty of discovering and proving that a competitor used the patented process. For patents where the process leaves identifiable fingerprints in the final API \u2014 specific trace impurities, specific isotope ratios, specific crystalline forms \u2014 infringement may be provable through product analysis without access to the manufacturing facility. For processes where no such fingerprint exists, proving infringement is substantially harder, and the process patent’s practical enforcement value is correspondingly reduced.<\/p>\n\n\n\n

Step 4: Portfolio Interaction Modeling<\/h3>\n\n\n\n

Process patents rarely operate in isolation. They interact with compound patents, formulation patents, and regulatory exclusivity in ways that affect their marginal value. A process patent that provides backup protection when a compound patent is invalidated has higher portfolio-level value than one that duplicates protection already provided by multiple other patent families.<\/p>\n\n\n\n

The portfolio interaction analysis should model:<\/p>\n\n\n\n

The sequential protection scenario: If the compound patent is invalidated through IPR or Paragraph IV litigation, what protection does the process patent provide, and for how long? This scenario assigns value to the process patent as insurance against compound patent invalidation.<\/p>\n\n\n\n

The post-compound expiration scenario: After the compound patent expires by its statutory term, what exclusivity does the process patent continue to provide, and how does it interact with remaining formulation or method patents?<\/p>\n\n\n\n

The licensing synergy scenario: In licensing negotiations with generic manufacturers, the process patent adds leverage even if neither the brand company nor the generic manufacturer believes it would be enforced in litigation. A patent portfolio that includes process patents covering the only commercially available synthesis routes is a stronger negotiating position than one that relies solely on compound claims.<\/p>\n\n\n\n

\n\n\n\n

How to Identify Process Patents in a Portfolio: The Data Challenge<\/h2>\n\n\n\n

One reason process patents are systematically undervalued in pharmaceutical portfolio analyses is that they are harder to identify than compound patents. The FDA’s Orange Book lists patents submitted by NDA holders as covering an “approved drug product or an approved method of using the drug product.” Process patents, which cover the manufacturing process rather than the product or its use, are explicitly excluded from Orange Book listing under 21 C.F.R. \u00a7 314.53(b) [15].<\/p>\n\n\n\n

This means that a pharmaceutical company’s process patents are not listed in the Orange Book and do not appear in the standard Hatch-Waxman patent identification workflow. An analyst who uses Orange Book patent listings as the starting point for portfolio analysis \u2014 as most do \u2014 will never see the process patents.<\/p>\n\n\n\n

Locating Process Patents in Patent Databases<\/h3>\n\n\n\n

Identifying process patents requires searching the USPTO database by assignee and filtering for patents with process-type claims, then manually reviewing claim language to identify synthesis route claims, purification method claims, and intermediate compound claims. This search can be substantially more efficient when guided by knowledge of the specific APIs covered by the product portfolio, allowing targeted chemical name and IPC\/CPC classification searches.<\/p>\n\n\n\n

DrugPatentWatch provides a useful bridge by linking Orange Book products to the broader patent landscape through patent family analysis \u2014 while process patents themselves are not Orange Book-listed, DrugPatentWatch’s patent family tracking can identify continuation and divisional applications from Orange Book patent families, some of which may have process-type claims. Patent families filed from the same parent application as a compound patent often include both compound claims and process claims, and identifying the full family reveals the process patent siblings that are invisible in Orange Book data alone.<\/p>\n\n\n\n

CMC Data as a Process Patent Map<\/h3>\n\n\n\n

The Chemistry, Manufacturing, and Controls sections of NDA submissions to the FDA contain detailed descriptions of the approved manufacturing process. For drugs where patents have expired or will soon expire, NDA holders occasionally seek to exploit a structural asymmetry: they know their own process, but generic ANDA filers must develop and disclose their own processes without access to the NDA’s confidential CMC data.<\/p>\n\n\n\n

Where an NDA holder has patented the manufacturing process described in its CMC section, the NDA CMC serves as an implicit map to where the process patents apply. Cross-referencing the patent portfolio against the publicly available portions of the NDA (the label, the FDA approval letter, any published CMC correspondence) and against the patent claims allows analysts to construct a schematic view of where process patent protection overlaps with the regulatory-approved manufacturing process.<\/p>\n\n\n\n

Drug Master Files: The Hidden Supply Chain Intelligence<\/h3>\n\n\n\n

API manufacturers who supply multiple customers (both branded and generic) frequently file Drug Master Files (DMFs) with the FDA describing their manufacturing processes. DMFs are confidential \u2014 the FDA can access them but drug product manufacturers can only reference them \u2014 but the existence and status of DMFs for specific APIs is publicly visible through the FDA’s DMF database [16].<\/p>\n\n\n\n

The DMF holder list for a specific API reveals which API manufacturers have developed and submitted manufacturing processes to the FDA for that compound. If a brand company holds process patents on the commercially available synthesis routes, and the DMF holders for the API are using those routes (which can sometimes be inferred from impurity profile data in ANDA submissions and from the process patent claims themselves), the DMF list becomes a map of potential infringers.<\/p>\n\n\n\n

This intelligence is commercially useful both offensively \u2014 identifying companies to approach for licensing discussions \u2014 and defensively, in anticipating which API suppliers are likely to supply generic ANDA filers and therefore which manufacturing processes will be introduced into the generic supply chain at launch.<\/p>\n\n\n\n

\n\n\n\n

Process Patent Prosecution Strategy: Writing Claims That Hold<\/h2>\n\n\n\n

The commercial value of a process patent depends critically on how the claims are written. Broad process claims may fail on anticipation or obviousness grounds. Narrow claims may be easily designed around. The prosecution strategy that maximizes commercial value occupies the space between these failure modes.<\/p>\n\n\n\n

Claiming at the Right Level of Specificity<\/h3>\n\n\n\n

A well-constructed process patent typically includes claims at multiple levels of specificity, creating a hierarchy analogous to the independent\/dependent claim structure in compound patents. The broadest independent claim captures the essential novel step or combination of steps at a level of generality that covers not only the exact process practiced commercially but also straightforward modifications that a generic manufacturer might attempt to design around.<\/p>\n\n\n\n

For a synthesis route patent, this might mean claiming the key bond-forming reaction (the step that establishes the most challenging structural feature of the API) in terms of the type of reaction and the reaction product, rather than the specific reagents, solvent, and temperature used commercially. This level of generality is more vulnerable to prior art challenges but more difficult to design around if it survives.<\/p>\n\n\n\n

Below that independent claim, dependent claims narrow progressively to the commercially practiced conditions: specific catalysts, specific solvents, specific temperature ranges, specific reaction times. These dependent claims provide the fallback protection that survives even if the broad independent claim is invalidated. A generic manufacturer who successfully invalidates the broad claim through IPR is still infringed by the dependent claim if it uses the specific conditions claimed.<\/p>\n\n\n\n

The Intermediate Compound Strategy<\/h3>\n\n\n\n

Claiming key synthetic intermediates as separate compound claims in the same patent family as the process claims provides a distinct claim type with different enforcement characteristics. Where a process claim requires proving that the competitor used the patented process, an intermediate compound claim requires proving that the competitor’s API contained \u2014 at some point in its manufacture \u2014 the patented intermediate structure.<\/p>\n\n\n\n

This can be provable through product analysis if the intermediate leaves detectable traces in the final API (residual solvents, characteristic impurities derived from the intermediate, or detectable trace amounts of the intermediate itself). It can also be provable through ANDA or regulatory filings that disclose the synthesis route, if the disclosed route requires passing through the patented intermediate.<\/p>\n\n\n\n

Filing intermediate compound claims in the same patent family as process claims also provides strategic flexibility in litigation. A process patent claim and an intermediate compound claim for the same synthesis pathway can be asserted simultaneously against the same defendant, requiring the defendant to contest both the process infringement theory and the intermediate compound theory \u2014 a more resource-intensive defense than if only one claim type were at issue.<\/p>\n\n\n\n

Continuation Applications for Manufacturing Evolution<\/h3>\n\n\n\n

Pharmaceutical manufacturing processes evolve over time. Process improvements \u2014 higher yield, reduced impurities, cheaper raw materials, shorter cycle times \u2014 generate new patentable subject matter that represents real commercial value to the manufacturer. A process patent prosecution strategy that files continuation applications to cover manufacturing improvements as they are developed creates a rolling portfolio that extends process patent coverage far beyond the term of the original process patent.<\/p>\n\n\n\n

This continuation strategy is legally permissible as long as the specification of the original parent application provides adequate support for the claims in the continuation. Since process patents covering synthesis routes often include relatively broad specifications describing the chemistry that could be modified in predictable ways, well-drafted parent specifications can support continuation claims covering process improvements that were not specifically exemplified in the original filing.<\/p>\n\n\n\n

For generic manufacturers seeking to enter a market after the compound patent expires, a brand company’s rolling process patent continuation portfolio creates a moving target. Each time the generic manufacturer completes its route design-around analysis, the brand company may have filed additional continuation claims covering modifications to the process that the generic manufacturer adopted as its alternative.<\/p>\n\n\n\n

\n\n\n\n

The ITC as an Enforcement Vehicle for Process Patents<\/h2>\n\n\n\n

While district court litigation under \u00a7 271(g) is the primary enforcement mechanism for process patents in the U.S. federal courts, the International Trade Commission provides a parallel enforcement pathway with distinct strategic characteristics. Both pathways deserve analysis in a complete process patent portfolio valuation.<\/p>\n\n\n\n

Section 337 Investigations: Scope and Timeline<\/h3>\n\n\n\n

Section 337 of the Tariff Act prohibits the importation of articles that infringe a valid U.S. patent [6]. For pharmaceutical process patents, the section 337 hook is the importation of the finished drug product or API made using the patented process. The ITC investigation process differs from district court patent litigation in several important ways.<\/p>\n\n\n\n

ITC investigations operate on a strict 12-to-18-month schedule set by the Administrative Law Judge, with limited ability to extend deadlines. Discovery is compressed but follows the Federal Rules of Civil Procedure. The evidentiary record is developed in parallel with district court proceedings, and ITC determinations can be appealed to the Federal Circuit.<\/p>\n\n\n\n

The strategic value of ITC proceedings for process patent enforcement is the exclusion order remedy. A limited exclusion order directing Customs to block importation of infringing APIs or drug products is immediately commercially disruptive to a generic manufacturer that cannot obtain a domestic API supply. Unlike a district court injunction, which requires a four-factor analysis and a court’s equitable discretion, an ITC exclusion order flows more directly from a finding of infringement.<\/p>\n\n\n\n

The Domestic Industry Requirement<\/h3>\n\n\n\n

ITC jurisdiction under Section 337 requires that there be a “domestic industry” in the United States that relates to the asserted patent [17]. For a brand pharmaceutical company asserting a process patent, the domestic industry requirement is generally satisfied by demonstrating domestic investments in research and development, manufacturing, or licensing activities relating to the patented process. Most large pharmaceutical companies satisfy this requirement with minimal difficulty.<\/p>\n\n\n\n

Generic API manufacturers who produce entirely in India or China, with no domestic manufacturing or R&D, may have more difficulty asserting their own process patents at the ITC if they later wish to use them offensively. This asymmetry in ITC access reinforces brand manufacturers’ relative advantage in ITC process patent enforcement.<\/p>\n\n\n\n

Customs Enforcement Mechanics<\/h3>\n\n\n\n

Even after an ITC exclusion order issues, enforcement requires educating U.S. Customs and Border Protection about how to identify and exclude the infringing articles. For a pharmaceutical API, where the infringing process may not be identifiable from physical inspection of the API, customs enforcement requires analytical testing protocols that can distinguish API produced by the patented process from API produced by other means.<\/p>\n\n\n\n

Where a process leaves a distinctive analytical signature \u2014 characteristic impurity profile, specific crystalline form, detectably different optical rotation \u2014 customs enforcement can be relatively straightforward. Where no such signature exists, customs enforcement requires either manufacturer declarations (which may be difficult to verify) or sampling and testing programs that introduce delay and uncertainty into the enforcement mechanism.<\/p>\n\n\n\n

The practical implication for process patent portfolio valuation is that exclusion order value should be discounted by the probability of effective customs enforcement, which depends on whether the infringing process leaves analytically detectable signatures in the final product.<\/p>\n\n\n\n

\n\n\n\n

Post-Grant Challenges to Process Patents: What the PTAB Record Shows<\/h2>\n\n\n\n

Process patents at the Patent Trial and Appeal Board (PTAB) face a specific prior art challenge landscape that differs from compound patent IPRs. Understanding this landscape is essential for realistic probability-of-survival estimates in the integrated valuation model.<\/p>\n\n\n\n

IPR Institution Rates for Process Claims<\/h3>\n\n\n\n

Petition institution rates for IPR proceedings at the PTAB have varied by technology area, and pharmaceutical process patents occupy a specific position in the distribution. The PTAB’s publicly available statistical reports show institution rates averaging around 56 to 67 percent across all technology areas between 2016 and 2023 [18]. Pharmaceutical technology area petitions, which include both compound and process patents, have generally tracked near the overall average.<\/p>\n\n\n\n

Process patent IPRs face a distinct anticipation challenge: synthetic chemistry has been practiced and published for over 150 years, and the chemical literature is vast. A well-resourced petitioner with access to chemical database searches can often find prior art describing similar or identical reaction steps, creating a plausible anticipation argument even against genuinely innovative process claims. The key variable is how specifically the claims define the novel aspect of the process \u2014 narrow, specific claims are harder to anticipate but easier to design around, while broad functional claims are more difficult to design around but more vulnerable to anticipation challenges.<\/p>\n\n\n\n

Prior Art Landscape Analysis for Synthesis Routes<\/h3>\n\n\n\n

The prior art landscape for pharmaceutical synthesis routes is searchable through chemical reaction databases that operate differently from patent text searches. SciFinder (now SciFinder-n) and Reaxys index chemical reactions by substrate, reagent, and product, allowing analysts to identify published reactions covering the same or closely related transformation claimed in the process patent. This prior art searching capability is distinct from the patent full-text searching used for compound patent IPRs, and the specialized expertise required to conduct it effectively is one reason why process patent IPR petitions are often less thoroughly developed than compound patent IPRs.<\/p>\n\n\n\n

For portfolio valuation, assessing prior art quality requires asking: are the published reactions disclosed in a way that teaches each element of the claimed process, or does the petitioner need to combine multiple references in a way that requires a hindsight-based rationale to combine? A process patent whose novel step involves a combination of known reactions in a non-obvious order or with an unexpected result is substantially more robust to anticipation challenges than one that assembles purely routine chemistry in a predictable arrangement.<\/p>\n\n\n\n

Freedom-to-Operate Opinions and Process Patent Design-Arounds<\/h3>\n\n\n\n

Generic manufacturers developing ANDA products for drugs covered by process patents routinely commission freedom-to-operate (FTO) opinions evaluating whether their proposed synthesis routes infringe any valid process patents. These opinions are non-public, but the existence of an FTO opinion seeking advice on specific process patents signals that the process patents were considered material enough to the generic manufacturer’s risk analysis to warrant paid legal review.<\/p>\n\n\n\n

For brand companies, understanding which process patents have attracted FTO analysis by generic developers \u2014 a conclusion that can sometimes be inferred from ANDA Paragraph IV certifications or from discussions in litigation discovery \u2014 provides intelligence about which patents in the process portfolio are considered relevant and enforceable by the generic industry. Patents that have never attracted FTO analysis despite the drug being a significant generic target may be either so strong that no one doubts their validity, or so narrow that no generic developer considered them worth analyzing.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Dimensions: How FDA Oversight Amplifies Process Patent Value<\/h2>\n\n\n\n

The FDA’s regulatory framework for pharmaceutical manufacturing creates a set of obligations that interact with process patent protection in ways that amplify the commercial value of strong process patents beyond their purely legal exclusionary scope.<\/p>\n\n\n\n

Chemistry, Manufacturing, and Controls Data Protection<\/h3>\n\n\n\n

NDA holders’ CMC data is protected from disclosure under 21 U.S.C. \u00a7 355(l), which provides a period of data exclusivity during which the FDA cannot approve an ANDA relying on the NDA holder’s preclinical and clinical data [19]. CMC data is separately protected under FDA’s regulations as confidential commercial information.<\/p>\n\n\n\n

This confidentiality regime means that generic ANDA filers cannot access the brand company’s manufacturing process data when developing their own manufacturing processes. They must independently develop, validate, and submit their own CMC data to the FDA. The confidentiality of brand company CMC data does not directly create patent protection, but it does create a practical barrier that reinforces process patent exclusivity.<\/p>\n\n\n\n

When a process patent covers the manufacturing approach that is most technically and economically feasible for the API, and that approach is also protected by CMC data confidentiality that prevents generic developers from learning the specific conditions used, the combination creates a double barrier: generic developers cannot copy the process without infringing, and they cannot learn the details of the process to design around it efficiently.<\/p>\n\n\n\n

ANDA CMC Review as an Infringement Detection Tool<\/h3>\n\n\n\n

The FDA’s review of generic ANDA submissions includes review of the CMC section describing the generic manufacturer’s proposed manufacturing process. While FDA review is not a patent infringement analysis, the CMC data submitted in an ANDA sometimes discloses the synthesis route in sufficient detail to allow the brand company’s process patent counsel to assess whether infringement is occurring.<\/p>\n\n\n\n

Under the Hatch-Waxman Act, brand companies receive notice of Paragraph IV certifications challenging listed Orange Book patents, which triggers the 30-month stay mechanism. But brand companies do not automatically receive CMC data from ANDA submissions. Obtaining that information requires either litigation discovery, requesting FDA to acknowledge a reference in the ANDA to a specific process patent (possible in limited circumstances), or using competitive intelligence methods to estimate the synthesis route from the generic manufacturer’s published disclosures and from the characteristics of the API they eventually place on the market.<\/p>\n\n\n\n

The imperfect information environment around generic manufacturing processes creates both a challenge and an opportunity for brand companies. The challenge is that proving infringement requires detective work that goes beyond reading the ANDA. The opportunity is that the same imperfect information environment creates uncertainty for generic manufacturers about whether their route will be challenged, which maintains the licensing leverage of the process patent portfolio even when direct enforcement is difficult.<\/p>\n\n\n\n

Drug Master Files and the Process Patent Connection<\/h3>\n\n\n\n

Recall that API manufacturers file Drug Master Files disclosing their manufacturing processes to the FDA. While the content of DMFs is confidential, the FDA’s list of DMF holders for specific APIs is public. When a brand company holds process patents covering the commercially available synthesis routes for an API, and the DMF holder list for that API reveals a finite number of suppliers, the brand company can target those specific suppliers with licensing inquiries or infringement assessments.<\/p>\n\n\n\n

Cross-referencing the DMF holder list with process patent claims requires chemical intelligence about which synthesis approaches are reflected in the claims \u2014 that is, which process patents correspond to the approaches that would realistically be described in a DMF for that API. This cross-referencing exercise is time-intensive but can identify the specific companies whose manufacturing processes may be at risk of infringement.<\/p>\n\n\n\n

DrugPatentWatch’s API and product-level data provides a useful starting point by identifying which API suppliers have historically supplied specific generic drug manufacturers, allowing a more targeted assessment of which suppliers’ DMFs are likely relevant to the process patent analysis.<\/p>\n\n\n\n

\n\n\n\n

Geographic Filing Strategy for Process Patents<\/h2>\n\n\n\n

The geographic dimension of process patent portfolios requires analysis along two separate axes: where the protected manufacturing process is practiced, and where the infringing products are ultimately sold.<\/p>\n\n\n\n

Filing in API Manufacturing Jurisdictions<\/h3>\n\n\n\n

The primary API manufacturing jurisdictions for pharmaceutical drugs sold in the United States are India (particularly the state of Andhra Pradesh and Telangana, where Hyderabad is a major generic manufacturing hub) and China (particularly Zhejiang, Shandong, and Hubei provinces). For a process patent to provide enforceable protection directly against the API manufacturer \u2014 rather than indirectly through \u00a7 271(g) at the point of import \u2014 the process patent must be filed in the jurisdiction where manufacturing occurs.<\/p>\n\n\n\n

Indian and Chinese process patents provide direct remedies against infringing manufacturers in those jurisdictions: injunctions against continued practice of the infringing process, and potentially damages. The procedural and practical challenges of enforcing a pharmaceutical process patent in Indian or Chinese courts are not trivial, but the existence of local process patents significantly strengthens the brand company’s negotiating position with API manufacturers and can be essential for obtaining injunctive relief in those jurisdictions.<\/p>\n\n\n\n

A process patent strategy that files only in the United States has a meaningful structural gap: it can pursue \u00a7 271(g) remedies against infringing imports at the point of entry into the United States, but it cannot directly stop manufacturing in India or China. A strategy that includes Indian and Chinese process patents closes this gap, at the cost of higher prosecution budgets.<\/p>\n\n\n\n

The Patent Cooperation Treaty and National Phase Strategy<\/h3>\n\n\n\n

The PCT system allows a single international patent application to be used as the basis for national phase applications in over 150 countries. The national phase deadline \u2014 typically 30 months from the priority date \u2014 provides the filing window during which the decision to nationalize must be made.<\/p>\n\n\n\n

For pharmaceutical process patents, the nationalization strategy should specifically include:<\/p>\n\n\n\n

India: The primary generic API manufacturing jurisdiction globally, with a patent system that has been more favorable to process patents than to certain categories of pharmaceutical compound patents since the 2005 amendments to the Indian Patents Act [20]. Notably, India’s patent law explicitly denies patents on new forms of known substances that do not result in enhanced efficacy (the Section 3(d) provision), but this restriction applies primarily to compound and formulation patents \u2014 process patents for novel synthesis routes generally remain eligible for protection under Indian patent law.<\/p>\n\n\n\n

China: The second major API manufacturing jurisdiction, with a patent system that has evolved significantly in recent years. Chinese process patent enforcement has historically been challenging, but recent reforms including the establishment of specialized IP courts in Beijing, Shanghai, and Guangzhou, and the introduction of punitive damages for willful infringement, have improved the enforcement environment materially [21].<\/p>\n\n\n\n

European Union: The German and UK generic pharmaceutical markets are significant, and several European countries host API manufacturing operations. Obtaining EPO process patents and validating them in key manufacturing countries provides protection against European-manufactured APIs.<\/p>\n\n\n\n

Brazil and South Korea: Both countries have significant generic pharmaceutical industries and domestic API manufacturing capacity for some compound classes, making process patent coverage in these jurisdictions commercially relevant for specific product portfolios.<\/p>\n\n\n\n

Lapse Monitoring as a Competitive Intelligence Signal<\/h3>\n\n\n\n

When a brand company allows process patent national phase entries or renewals to lapse in specific jurisdictions, it signals a reassessment of the commercial value of that protection. Monitoring competitors’ process patent lapse activity \u2014 by tracking the status of their international patent families through databases like Espacenet and the WIPO PatentScope database \u2014 provides early intelligence about which drugs they have concluded are no longer commercially defensible through process patents.<\/p>\n\n\n\n

A brand company that begins allowing its process patent renewals to lapse in major generic manufacturing jurisdictions three to four years before its compound patent expires may be signaling internal doubt about the commercial value of its process patent position. That signal has implications both for competitors assessing the vulnerability of the brand’s position and for investors evaluating the asset’s future revenue durability.<\/p>\n\n\n\n

\n\n\n\n

Building a Process Patent Portfolio: Integration with Compound and Formulation IP<\/h2>\n\n\n\n

Process patents do not operate in isolation. Their commercial value is highest when they are consciously integrated with compound patents, formulation patents, and regulatory exclusivity into a unified portfolio strategy that creates multiple independent layers of protection.<\/p>\n\n\n\n

Timing the Process Patent Filing<\/h3>\n\n\n\n

The optimal timing for process patent filing relative to compound patent filing reflects a specific constraint: a process patent must have a specification that adequately describes and enables the claimed process, which typically requires that the manufacturing process has been developed to at least laboratory scale. For early-stage pharmaceutical discovery programs, where large-scale synthesis routes have not yet been developed, process patents cannot be meaningfully filed.<\/p>\n\n\n\n

The practical consequence is that process patents in pharmaceutical portfolios are usually filed one to three years after the initial compound patent, once the development team has optimized a synthesis route for API production campaigns supporting clinical trials. This later filing date means that process patents typically have a term two to three years shorter than the compound patent they complement.<\/p>\n\n\n\n

However, this timing creates an opportunity for a systematic portfolio strategy: process patents on manufacturing improvements can be filed throughout the product’s commercial life, as process optimization generates patentable improvements. A brand company that treats process patent filing as a one-time event loses this opportunity. One that treats it as a continuous program maintains a rolling portfolio of process protection with staggered expiration dates.<\/p>\n\n\n\n

Process Patents as Anti-Generic-First-Mover Tools<\/h3>\n\n\n\n

The 180-day exclusivity period granted to the first generic manufacturer to file an ANDA with a successful Paragraph IV certification creates a powerful economic incentive for “first filer” competition among generic manufacturers. The first filer who successfully certifies against compound or formulation patents and prevails in subsequent litigation earns a 180-day period during which no other generic can launch, creating a temporary duopoly with premium generic pricing.<\/p>\n\n\n\n

Process patents that are not Orange Book-listed cannot be the basis of Paragraph IV certifications and therefore cannot generate 30-month stays or 180-day exclusivity for generic first filers. But they can complicate the first filer’s commercial launch in ways that indirectly benefit the brand company.<\/p>\n\n\n\n

A first filer who launches the generic product and begins selling \u2014 creating 180-day exclusivity \u2014 but whose API was made by a process covered by a brand company’s process patent faces infringement liability from the moment of launch. The brand company can file a process patent infringement suit in district court without the safe harbor provisions of Hatch-Waxman, which apply only to the compound and formulation patents listed in the Orange Book [22].<\/p>\n\n\n\n

This threat can affect the first filer’s risk calculus at launch. Some first filers negotiate licenses to process patents as part of their overall settlement discussions with brand companies, producing royalty streams that continue even after the generic product is on market.<\/p>\n\n\n\n

The Formulation-Process Interface<\/h3>\n\n\n\n

For extended-release and other complex dosage form patents, the line between a formulation patent (which is Orange Book-listable) and a process patent (which is not) can be technically ambiguous. A patent claiming a method of producing an extended-release tablet that requires specific processing steps \u2014 high-shear granulation conditions, specific spray-drying parameters, or a multi-step hot-melt extrusion process \u2014 may be characterized as either a formulation patent on the product or a process patent on the manufacturing method, depending on how the claims are drafted.<\/p>\n\n\n\n

Strategic claim drafting that presents process-intensive formulation technology as product claims \u2014 describing the product by its physical characteristics achieved through the process, rather than by the process steps themselves \u2014 can produce Orange Book-listable patents that provide process-type protection with the additional benefit of Hatch-Waxman regulatory enforcement advantages. Courts have sometimes allowed product-by-process claims in pharmaceuticals, though the Federal Circuit has generally required that a product claim be limited to the product as produced by the claimed process only where the product itself cannot be described structurally [23].<\/p>\n\n\n\n

Patent counsel drafting claims for complex formulations should analyze the claim drafting strategy from this perspective: the choice between a product claim, a product-by-process claim, and a pure process claim has significant commercial implications for Orange Book listability and Hatch-Waxman enforcement access.<\/p>\n\n\n\n

\n\n\n\n

Process Patents and Biologic Manufacturing: The Biosimilar-Specific Analysis<\/h2>\n\n\n\n

For biological products, process patent strategy requires a separate analytical framework that accounts for the fundamental differences between small-molecule and biologic manufacturing, the distinct biosimilar regulatory pathway under the BPCIA, and the specific technical challenges of proving biologic process patent infringement.<\/p>\n\n\n\n

The Cell Line Patent Distinction<\/h3>\n\n\n\n

Cell line patents cover the specific recombinant cell line \u2014 the host cell transfected with an expression vector encoding the protein of interest \u2014 used to produce a biologic. They differ from process patents in that they cover a biological material rather than a sequence of manufacturing steps, but they create analogous exclusionary effects. A biosimilar manufacturer who wants to use the same cell line as the reference product manufacturer cannot do so without licensing or developing an alternative expression system.<\/p>\n\n\n\n

The commercial value of cell line patents depends on whether comparable alternative cell lines can be developed and whether those alternative cell lines produce a protein that meets regulatory biosimilarity standards. For monoclonal antibodies, where CHO cell expression is the dominant commercial platform, alternative cell systems (HEK293, NS0, Sp2\/0) exist but each produces proteins with different glycosylation patterns that may affect clinical comparability.<\/p>\n\n\n\n

The FDA’s biosimilar approval pathway explicitly contemplates that biosimilars will be manufactured using different processes than the reference product, and the analytical characterization and sometimes clinical similarity studies required for biosimilar approval accommodate the resulting molecular differences within defined limits. This regulatory design partially decouples biologic manufacturing process patents from biosimilar entry in a way that has no analog in small-molecule generic entry.<\/p>\n\n\n\n

Downstream Processing Patents: Higher Enforcement Value in Biologics<\/h3>\n\n\n\n

While upstream process patents (cell line, culture conditions) face biosimilar design-around facilitated by the regulatory framework’s tolerance for process differences, downstream processing patents may have higher enforcement value for biologics precisely because downstream processes are more constrained by the product’s physical chemistry and regulatory requirements.<\/p>\n\n\n\n

The purification of a monoclonal antibody from cell culture supernatant involves a defined sequence of chromatography steps \u2014 typically protein A affinity capture, followed by ion exchange chromatography, followed by size exclusion or additional polishing steps \u2014 that are constrained by the protein’s binding properties and the regulatory requirements for process-related impurity clearance. Viral inactivation and filtration steps are constrained by the ICH Q5A guidance requirements for biological products [24].<\/p>\n\n\n\n

These regulatory constraints reduce the design space for downstream processing, meaning that different manufacturers’ downstream processes may converge on similar approaches not because they copied each other but because the regulatory and technical constraints drive them toward similar solutions. A downstream processing patent that claims a broadly applicable approach \u2014 rather than a narrowly specific condition \u2014 can capture this convergent space.<\/p>\n\n\n\n

The enforcement implication is that downstream biologic process patents can be asserted against biosimilar manufacturers who have independently developed their downstream processes to comply with the same regulatory requirements that drove the original patentee to the same approach. The technical similarity required for biosimilarity provides circumstantial evidence that the biosimilar manufacturer’s downstream process resembles the reference manufacturer’s, which is the starting point for a process infringement analysis.<\/p>\n\n\n\n

The Analytical Comparability Bridge<\/h3>\n\n\n\n

Proving infringement of a biologic process patent presents a specific evidentiary challenge: the allegedly infringing “product made by process” is a complex biological molecule, and its manufacturing process cannot be directly analyzed from the product in the way that a small-molecule API’s synthesis route sometimes can be inferred from its impurity profile.<\/p>\n\n\n\n

However, advances in glycoproteomics and other analytical techniques have created new methods for inferring aspects of a protein’s manufacturing process from its molecular characteristics. Glycosylation patterns, glycoform distributions, aggregation profiles, and post-translational modification patterns all reflect the manufacturing conditions used to produce the protein. A biosimilar antibody’s glycan profile, for example, can indicate whether it was produced in a CHO cell system under specific culture conditions, or whether a different cell line or culture approach was used.<\/p>\n\n\n\n

This analytical comparability evidence does not prove process infringement in the same direct way that finding a specific impurity in a small-molecule API can, but it can establish the statistical likelihood that a particular manufacturing approach was used, creating the factual predicate for a \u00a7 295 burden shift or supporting a circumstantial infringement case in district court.<\/p>\n\n\n\n

\n\n\n\n

The Competitive Intelligence Use Case: Monitoring Competitor Process Patent Portfolios<\/h2>\n\n\n\n

The same analytical framework that values your own process patent portfolio can be applied to competitor portfolios to identify their vulnerabilities and the timing of their generic cliffs more precisely than compound patent analysis alone permits.<\/p>\n\n\n\n

Mapping Competitor Process Patents to Their Generic Timeline<\/h3>\n\n\n\n

A competitor’s compound patent expiration is publicly known and heavily analyzed. Its process patent expiration is often unknown to outside analysts, which means that correct competitive intelligence about process patent term can provide genuine predictive advantage in forecasting when a competitor’s generic entry will actually occur versus when its compound patent expires.<\/p>\n\n\n\n

For a drug where the competitor holds process patents on the only commercially available synthesis route, generic entry may be delayed not merely until the compound patent expires, but until the process patents also expire or are successfully designed around. If those process patents expire two or three years after the compound patent, the correct generic entry date is the process patent expiration, not the compound patent expiration.<\/p>\n\n\n\n

Building this competitor analysis requires:<\/p>\n\n\n\n

Identifying the competitor’s full patent portfolio for each material drug, including patents not Orange Book-listed.<\/p>\n\n\n\n

Assessing which of those patents cover manufacturing processes rather than compound or formulation claims.<\/p>\n\n\n\n

Analyzing whether commercially viable alternative routes exist that generic manufacturers can use to design around the process patents.<\/p>\n\n\n\n

Estimating the time and cost required for route design-around versus licensing.<\/p>\n\n\n\n

Constructing an adjusted generic entry timeline based on this complete picture.<\/p>\n\n\n\n

DrugPatentWatch’s patent family tracking provides the starting point by identifying the full patent family associated with a drug product, which often includes process patent family members even when they are not individually listed in the Orange Book. Cross-referencing those family members with USPTO and international patent records identifies the complete scope of process protection.<\/p>\n\n\n\n

Identifying Gaps in Competitor Process Coverage<\/h3>\n\n\n\n

The inverse analysis \u2014 identifying where a competitor has compound patent protection but limited or no process patent coverage \u2014 reveals vulnerability that a well-resourced generic manufacturer can exploit. A drug with a robust compound patent and no process patent protection is a simpler generic development target than one with both layers intact.<\/p>\n\n\n\n

This gap analysis has specific commercial applications:<\/p>\n\n\n\n

For a generic manufacturer assessing which development projects to prioritize, identifying compound patent-only targets versus compound-plus-process patent targets affects the development cost, timeline, and risk profile of each project.<\/p>\n\n\n\n

For a brand company that has acquired a competitor’s drug through M&A, identifying gaps in the acquired product’s process patent coverage reveals where investment in route development and patent filing could extend protection that the original developer failed to establish.<\/p>\n\n\n\n

For investment analysts assessing generic pharmaceutical companies’ pipeline quality, distinguishing between targets with and without process patent coverage provides more accurate revenue timing projections than analysis based solely on compound patent expiration dates.<\/p>\n\n\n\n

\n\n\n\n

Integration into the Full Portfolio Valuation: Putting Process Patents in Context<\/h2>\n\n\n\n

The complete valuation framework for a pharmaceutical patent portfolio, of the type described in the companion analysis of advanced portfolio metrics, adds the process patent analysis as a distinct layer that contributes to and modifies the overall portfolio value estimate.<\/p>\n\n\n\n

Where Process Patents Change the Valuation Output<\/h3>\n\n\n\n

Process patents affect the portfolio valuation output in three specific ways that compound and formulation patent analysis cannot capture.<\/p>\n\n\n\n

First, they extend the effective exclusivity timeline for specific products beyond the compound patent expiration date, increasing the duration of the protected revenue stream in the discounted cash flow model. For a drug where compound patent expiration occurs five years before process patent expiration, the DCF model should use the process patent expiration date as the effective end of exclusivity, with a probability discount reflecting the likelihood of route design-around during the intervening period.<\/p>\n\n\n\n

Second, they generate a distinct licensing revenue stream from generic manufacturers who choose to license the process technology rather than develop alternative routes. This licensing stream appears in the revenue model as a post-exclusivity cash flow \u2014 smaller than branded revenue, but materially larger than zero, and with a duration that extends to the process patent’s expiration date.<\/p>\n\n\n\n

Third, they modify the invalidation probability of the compound patent in the DCF model by providing backup protection that reduces the cost of compound patent invalidation. A compound patent with no process patent backup, when invalidated, results in immediate generic entry. A compound patent with strong process patent backup, when invalidated, results in a licensing negotiation with generic manufacturers who still cannot freely use the most efficient manufacturing process. This backup value should be modeled as a reduction in the expected revenue loss from compound patent invalidation scenarios.<\/p>\n\n\n\n

Presenting Process Patent Value to Non-Technical Decision-Makers<\/h3>\n\n\n\n

A portfolio valuation report that includes process patent analysis must translate highly technical chemistry and manufacturing law into terms that financial and strategic decision-makers can evaluate. The most effective framing positions the process patent analysis around three questions that any businessperson can understand:<\/p>\n\n\n\n

Can a generic manufacturer produce this drug without our permission? This is the route-dependency question, answered in plain terms about whether alternative synthesis approaches exist and how long they would take to develop and validate.<\/p>\n\n\n\n

If they can, how long will it take and how much will it cost them? This is the regulatory switching cost question, answered in calendar months and dollar estimates that a CFO can relate to standard pharmaceutical development benchmarks.<\/p>\n\n\n\n

If they need to license from us, what are the terms we can realistically command? This is the licensing leverage question, answered with a probability-weighted estimate of the royalty rate achievable in arm’s-length negotiations, benchmarked against disclosed pharmaceutical process technology licensing transactions where available.<\/p>\n\n\n\n

These three questions, answered quantitatively with appropriate probability adjustments, translate the technical process patent analysis into a contribution to portfolio value that sits alongside and complements the compound and formulation patent analysis.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

Process patents cover synthesis routes, purification methods, key synthetic intermediates, and biologic manufacturing processes. They are excluded from Orange Book listing, which means standard Hatch-Waxman patent analysis misses them entirely. Analysts who start with the Orange Book have a structural blind spot.<\/p>\n\n\n\n

35 U.S.C. \u00a7 271(g) provides a direct infringement claim against importers of products made by a U.S.-patented process. Since the majority of pharmaceutical API manufacturing for U.S. markets occurs in India and China, this statute creates enforceable rights against the generic supply chain regardless of where manufacturing occurs.<\/p>\n\n\n\n

The burden shift under 35 U.S.C. \u00a7 295 moves the proof-of-non-infringement obligation to the accused generic manufacturer once the patent holder establishes a likelihood of infringement. This burden shift is commercially powerful because generic manufacturers rarely want to disclose their manufacturing processes in litigation.<\/p>\n\n\n\n

Route-dependency analysis \u2014 determining whether commercially viable alternative synthesis routes exist \u2014 is the foundational step in process patent valuation. Patents on the only commercially feasible route to an API provide near-compound-patent-level protection. Patents on one of several available routes provide leverage but not exclusivity.<\/p>\n\n\n\n

Regulatory switching costs multiply the commercial value of process patents beyond their direct exclusionary scope. The FDA’s CMC approval requirement for route changes creates a 12-to-24-month switching cost that generic manufacturers must weigh against licensing the process directly.<\/p>\n\n\n\n

The ITC Section 337 enforcement pathway provides an importation-based remedy \u2014 the exclusion order \u2014 that can be obtained in 12 to 16 months, much faster than district court litigation, and can apply to imported APIs made by patented processes.<\/p>\n\n\n\n

Biologic process patents operate differently from small-molecule process patents because the BPCIA regulatory framework expects biosimilars to use different manufacturing processes. Downstream processing patents with broad functional claims have higher enforcement value in biologics than upstream cell culture patents, because regulatory constraints reduce the downstream design space.<\/p>\n\n\n\n

Geographic filing strategy for process patents must specifically include India and China \u2014 the primary API manufacturing jurisdictions \u2014 to provide direct remedies against API manufacturers rather than relying solely on \u00a7 271(g) import remedies.<\/p>\n\n\n\n

Drug Master File holder lists, ANDA filing data, and patent family tracking available through tools like DrugPatentWatch provide the data infrastructure for identifying which API suppliers’ processes may infringe, which generic manufacturers are developing products in the relevant space, and where process patent coverage gaps leave branded products vulnerable.<\/p>\n\n\n\n

A portfolio valuation that incorporates process patent analysis produces materially different \u2014 and more accurate \u2014 revenue timeline projections than one based solely on compound and formulation patents. The systematic omission of process patent analysis from standard pharmaceutical IP valuations represents a consistent source of undervaluation in M&A transactions, licensing negotiations, and strategic planning.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/h2>\n\n\n\n

Q1: Can a brand pharmaceutical company list a process patent in the FDA’s Orange Book to gain Hatch-Waxman enforcement advantages?<\/strong><\/p>\n\n\n\n

A1: No. 21 C.F.R. \u00a7 314.53(b) explicitly prohibits the listing of process patents in the Orange Book. The listing requirement applies to patents that “claim the drug substance (active ingredient), drug product (formulation or composition), or an approved method of using the drug.” Manufacturing process patents \u2014 those claiming synthesis routes, purification methods, or production steps \u2014 do not satisfy this criterion and cannot be listed. The consequence is significant: unlisted process patents cannot trigger the 30-month stay of FDA ANDA approval that Orange Book-listed patents can trigger through Paragraph IV certification. Process patent holders must rely on district court litigation under \u00a7 271(g) or ITC Section 337 proceedings for enforcement, without the procedural advantages of the Hatch-Waxman framework. One partial workaround is drafting claims for manufacturing-intensive formulations as product claims (describing the product by characteristics produced by the process) rather than pure process claims, potentially achieving Orange Book eligibility \u2014 but courts and the FDA scrutinize product-by-process claims carefully, and the strategy carries meaningful prosecution and listing risk.<\/p>\n\n\n\n

Q2: How does the “materially changed” limitation in \u00a7 271(g) affect process patent enforcement against pharmaceutical imports?<\/strong><\/p>\n\n\n\n

A2: The “materially changed by subsequent processes” limitation in 35 U.S.C. \u00a7 271(g) is the primary defense generic manufacturers raise against process patent import infringement claims. Courts have interpreted “materially changed” narrowly in the pharmaceutical context. In Bio-Technology General Corp. v. Genentech, Inc., the Federal Circuit held that chemical changes that significantly alter the structure and properties of the product \u2014 not merely formulation or finishing steps \u2014 can constitute a material change [25]. For pharmaceutical APIs, standard formulation steps (blending the API with excipients, tableting, coating, or filling into capsules) have generally not qualified as material changes because they do not alter the chemical structure of the API itself. A subsequent step that converts the API to a different salt form, a different polymorph, or a different chemical entity might qualify, but this requires genuine chemical transformation, not mere physical processing. The practical implication for process patent enforcement is that import claims are most durable when the patented process covers API synthesis steps, and the imported product is either the API itself or a dosage form that contains the API in its originally-produced chemical form.<\/p>\n\n\n\n

Q3: When a pharmaceutical company acquires a drug through M&A, how should the due diligence process evaluate process patents that the target company may not have fully identified or documented?<\/strong><\/p>\n\n\n\n

A3: Process patent due diligence in pharmaceutical M&A requires a separate work stream from compound and formulation patent review, and it should be conducted by counsel with both patent prosecution experience and pharmaceutical chemistry expertise. The starting point is a comprehensive patent portfolio search for the target company, by assignee name and all predecessor entities, specifically filtering for patents with process-type claim language \u2014 claims reciting steps, methods, reacting, purifying, isolating, or producing. This search will surface process patents that did not appear in the Orange Book review. For each process patent identified, the diligence team should assess whether the patented process reflects the manufacturing approach currently used by the target’s API suppliers (which requires reviewing the target’s manufacturing agreements and CMC documentation), whether the process patents cover manufacturing approaches that generic developers would realistically use, and whether the process patents have been asserted or licensed in the past. A specific red flag in pharmaceutical M&A process patent diligence is the situation where the target company holds process patents on a manufacturing approach that its own current API supplier uses, but has never audited whether that supplier’s process actually infringes a competitor’s process patent. Post-acquisition discovery of a process patent infringement claim against the acquired product’s API supply chain can be commercially disruptive and is a specific representation and warranty risk that should be addressed in deal documentation.<\/p>\n\n\n\n

Q4: How should analysts assess the validity risk of a process patent that covers a synthesis route described in academic literature published before the patent filing date?<\/strong><\/p>\n\n\n\n

A4: Prior art in the academic chemistry literature is the primary validity risk for pharmaceutical process patents, and assessing this risk requires substantially different search methodology than assessing compound patent prior art. Reaction databases (SciFinder-n, Reaxys) index chemical transformations by reaction type, substrate class, and product, allowing prior art searches that identify published descriptions of the same or closely analogous reactions. The relevant validity question is whether the published prior art discloses each element of the claimed process \u2014 the specific transformation, the conditions, and any key intermediates \u2014 either in a single reference (anticipation) or in a combination of references that a skilled process chemist would have been motivated to combine (obviousness). Where the academic literature describes the same reaction type using different substrates or different conditions, the obviousness analysis turns on whether the claimed conditions or substrate scope would have been predictable to a skilled process chemist. Patents on genuinely novel synthetic methodology \u2014 new catalytic systems, new reagent combinations, new reaction types \u2014 are more robust against academic literature prior art. Patents on applications of known methodology to specific pharmaceutical substrates are more vulnerable, because the “motivation to try” and “reasonable expectation of success” standards for obviousness are easier to satisfy when the reaction type itself is well-established and the only variable is the substrate.<\/p>\n\n\n\n

Q5: What is the relationship between process patent strategy and the FDA’s increasing scrutiny of nitrosamine and other process-related impurities?<\/strong><\/p>\n\n\n\n

A5: The FDA’s guidance on nitrosamine impurities, which began in 2018 following the valsartan recall and has continued with subsequent guidance documents covering ranitidine, metformin, and other drug classes, has created a new commercial dynamic for pharmaceutical process patents [26]. Manufacturers who developed and patented synthesis routes that inherently avoid nitrosamine formation pathways \u2014 either by eliminating secondary amine intermediates, using non-nitrosating reagents, or incorporating validated nitrosamine clearance steps \u2014 hold an IP position with direct commercial value in the current regulatory environment. Generic manufacturers who used synthesis routes that generate nitrosamine impurities above acceptable limits have faced recalls, warning letters, and supply disruptions. A brand manufacturer that holds process patents covering nitrosamine-free synthesis approaches, and whose marketed product has a clean impurity profile that competitors’ generics cannot match without route changes, occupies a uniquely favorable competitive position. This regulatory-IP intersection also creates a new category of process patent value in portfolio analysis: patents covering manufacturing approaches that produce cleaner impurity profiles than available alternatives carry commercial value not only as exclusionary tools but as quality differentiators that can support premium pricing and formulary preference even in commodity generic markets. FDA’s increasing emphasis on impurity profiling under ICH Q3A and Q3B guidelines, combined with the specific nitrosamine regulatory framework, has permanently elevated the commercial significance of pharmaceutical manufacturing process IP.<\/p>\n\n\n\n

\n\n\n\n

Sources<\/h2>\n\n\n\n

[1] European Medicines Agency. (2019). EMA’s review of medicines containing valsartan: Outcome of a procedure under Article 31 of Directive 2001\/83\/EC<\/em> (EMA\/145682\/2019). EMA. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valsartan-article-31-referral-ema-review-valsartan-medicines-outcome_en.pdf<\/p>\n\n\n\n

[2] International Council for Harmonisation. (2004). Q5E: Comparability of biotechnological\/biological products subject to changes in their manufacturing process<\/em>. ICH. https:\/\/www.ich.org\/page\/quality-guidelines<\/p>\n\n\n\n

[3] 35 U.S.C. \u00a7 271(g). (2024). Infringement of patent: Products made by patented processes<\/em>. United States Code.<\/p>\n\n\n\n

[4] 35 U.S.C. \u00a7 271(g)(1)\u2013(2). (2024). Limitations on process patent infringement<\/em>. United States Code.<\/p>\n\n\n\n

[5] Bayer AG v. Housey Pharmaceuticals, Inc., 340 F.3d 1367 (Fed. Cir. 2003).<\/p>\n\n\n\n

[6] 19 U.S.C. \u00a7 1337. (2024). Unfair practices in import trade<\/em>. United States Code.<\/p>\n\n\n\n

[7] United States International Trade Commission. (2023). ITC Section 337 investigations: Fiscal year 2023 statistics<\/em>. USITC.<\/p>\n\n\n\n

[8] 35 U.S.C. \u00a7 295. (2024). Presumption: Product made by patented process<\/em>. United States Code.<\/p>\n\n\n\n

[9] 21 C.F.R. \u00a7 314.70. (2024). Supplements and other changes to an approved application<\/em>. Code of Federal Regulations.<\/p>\n\n\n\n

[10] U.S. Food and Drug Administration. (2011). Process validation: General principles and practices<\/em> (Guidance for Industry). FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/process-validation-general-principles-and-practices<\/p>\n\n\n\n

[11] Holton, R. A., Biediger, R. J., & Boatman, P. D. (1995). Semisynthesis of taxol and taxotere. In V. Farina (Ed.), The chemistry and pharmacology of taxol and its derivatives<\/em> (pp. 97\u2013121). Elsevier.<\/p>\n\n\n\n

[12] Pfizer Inc. (2012). Annual report 2011 (Form 10-K)<\/em>. U.S. Securities and Exchange Commission.<\/p>\n\n\n\n

[13] Roth, B. D. (2002). The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Progress in Medicinal Chemistry, 40<\/em>, 1\u201322. https:\/\/doi.org\/10.1016\/S0079-6468(08)70080-8<\/p>\n\n\n\n

[14] Storring, P. L., & Gaines Das, R. E. (1992). The International Standard for Recombinant DNA-derived Human Erythropoietin. Journal of Endocrinology, 134<\/em>(3), 459\u2013484.<\/p>\n\n\n\n

[15] 21 C.F.R. \u00a7 314.53(b). (2024). Submission of patent information<\/em>. Code of Federal Regulations.<\/p>\n\n\n\n

[16] U.S. Food and Drug Administration. (2024). Drug master files (DMFs)<\/em>. FDA. https:\/\/www.fda.gov\/drugs\/forms-submission-requirements\/drug-master-files-dmfs<\/p>\n\n\n\n

[17] 19 U.S.C. \u00a7 1337(a)(3). (2024). Domestic industry requirement<\/em>. United States Code.<\/p>\n\n\n\n

[18] United States Patent and Trademark Office. (2023). Patent trial and appeal board statistics: FY2023<\/em>. USPTO. https:\/\/www.uspto.gov\/patents\/ptab\/statistics<\/p>\n\n\n\n

[19] 21 U.S.C. \u00a7 355(l). (2024). Data exclusivity for new drug applications<\/em>. United States Code.<\/p>\n\n\n\n

[20] The Patents (Amendment) Act, 2005. (2005). No. 15 of 2005. Government of India. https:\/\/ipindia.gov.in\/patents.htm<\/p>\n\n\n\n

[21] National People’s Congress. (2020). Patent Law of the People’s Republic of China (fourth revision)<\/em>. Standing Committee of the NPC.<\/p>\n\n\n\n

[22] Eli Lilly and Co. v. Medtronic, Inc., 496 U.S. 661 (1990).<\/p>\n\n\n\n

[23] Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009).<\/p>\n\n\n\n

[24] International Council for Harmonisation. (1999). Q5A(R1): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin<\/em>. ICH. https:\/\/www.ich.org\/page\/quality-guidelines<\/p>\n\n\n\n

[25] Bio-Technology General Corp. v. Genentech, Inc., 80 F.3d 1553 (Fed. Cir. 1996).<\/p>\n\n\n\n

[26] U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs<\/em> (Guidance for Industry, Revision 2). FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs<\/p>\n","protected":false},"excerpt":{"rendered":"

The Hierarchy Problem in Pharmaceutical IP Every pharmaceutical patent portfolio has a hierarchy, whether the company managing it acknowledges one […]<\/p>\n","protected":false},"author":1,"featured_media":37097,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37096"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37096\/revisions"}],"predecessor-version":[{"id":37098,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37096\/revisions\/37098"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37097"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}